News

Date Title and Summary
Toggle Summary Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer
SAN DIEGO --(BUSINESS WIRE)--Dec. 28, 2017-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA , a multinational,
Toggle Summary Odonate Therapeutics Announces Closing of Initial Public Offering
SAN DIEGO --(BUSINESS WIRE)--Dec. 11, 2017-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its initial public offering of
Toggle Summary Odonate Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO --(BUSINESS WIRE)--Dec. 6, 2017-- Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering
Toggle Summary Susan G. Komen® Launches Its First Crowdfunding Initiative To Support Metastatic Breast Cancer Research
Your Generous Donation, Supported by a Dollar-for-Dollar Match from Odonate Therapeutics™, Will Go toward Advancing the Treatment of Patients Suffering from the Leading Cause of Cancer Deaths in Women Worldwide DALLAS and SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Individuals and organizations looking
Back to Top